AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03423849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1250mg/m2,day 1 to day 14, every 3 weeks
Study NCT03472508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril Maleate and Folic Acid Tablets (Yiye)
Description: Enalapril Maleate and Folic Acid Tablets (Yiye) have been approved for listing by the China Food and Drug Administration. Approval number: Zhunzi H20103723.All drugs used in the double-blind treatment period of this study will be loaded into safety capsules with the same outer appearance; all parties involved in the trial will be unaware of the contents of the capsules.
Study NCT03472508 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Enalapril
Description: Enalapril used in this study are listed products. All drugs used in the double-blind treatment period of this study will be loaded into safety capsules with the same outer appearance; all parties involved in the trial will be unaware of the contents of the capsules.
Study NCT01736956 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fetal Aortic Valvuloplasty
Description: Fetuses in the intervention group will undergo in utero balloon aortic valvuloplasty via a transuterine, perventricular approach. Fetuses in the control group will have no invasive intervention while in utero.
Study NCT00456313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLIXOTIDE and SERETIDE
Description: comparator
Study NCT03557567 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: NGS molecular screening
Study NCT04664348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Posteroanterior mobilization (neutral)
Description: Positioning of the patient: Prone position with the lumbar area uncovered.~Positioning of the therapist: Stand to one side of the table at the pelvis of the patient.~Explanation of the technique: The contact will be made with the hypothenar eminence on the spinous processes to be treated. The other hand of the physiotherapist will reinforce the grip to obtain greater stability and precision. It will proceed to carry out some posteroanterior pushes of the target vertebrae, in order to desensitize the chosen area. The force exerted and the speed of the technique will be controlled by the therapist. The technique will be finished when the participant let the therapist know when the pain is gone or when the patient no longer refer a decrease on its pain.~Both groups: The patient will be provided with a list of exercises focused on improving resistance to mechanical load in the lumbar region. The completion of the exercise will be in the 6 weeks of the duration of the treatment.
Study NCT04664348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Posteroanterior mobilization (extension)
Description: Positioning of the patient: Prone position with the lumbar area uncovered. The head of the stretcher will be raised upwards, placing progressively to extend the lumbar region, until the patient communicates the reproduction of its symptoms.~Positioning of the therapist: Stand to one side of the table at the pelvis of the patient.~Explanation of the technique: The contact will be made with the hypothenar eminence on the spinous processes to be treated. The other hand of the physiotherapist will reinforce the grip to obtain greater stability and precision. It will proceed to carry out some posteroanterior pushes of the target vertebrae, in order to desensitize the chosen area. The force exerted and the speed of the technique will be controlled by the therapist. The technique will be finished when the participant let the therapist know when the pain is gone or when the patient no longer refer a decrease on its pain.
Study NCT00566384 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment with daily oral intake of two capsules containing Placebo. Treatment duration will be 24 weeks
Study NCT04900532 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tocotrienol rich fraction
Description: Supplementation with a Vitamin E compound.
Study NCT04900532 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo containing 0,96mg of tocotrienol and 1,76mg of tocopherol twice a day for three months.
Study NCT02255435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone Capsules, 2.5 mg
Study NCT00304083 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously
Study NCT00304083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00304083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT02255435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone Capsules, 5 mg
Study NCT02255435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone Capsules, 10 mg
Study NCT02255435 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02255435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone Capsules, 20 mg
Study NCT02255435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone Capsules, 40 mg
Study NCT02255435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone Capsules, 80 mg
Study NCT02255435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone Capsules, 160 mg
Study NCT02255435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone Capsules, 300 mg
Study NCT02255435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone Capsules, 150 mg
Study NCT02731742 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-1966
Description: MK-1966 administered as an intravenous (IV) infusion
Study NCT03278054 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Root Canal Treatment with hand instruments
Description: Root canal treatment was performed with K files.
Study NCT03278054 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Root canal treatment with Protaper instruments
Description: Root canals were enlarged with S1 S2 F1F2 F2 Protaper instruments
Study NCT03278054 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Root canal treatment with hybrid instrumentation
Description: Root canal were enlarged with combination of a combination of ProTaper Universal instruments to shape the coronal and middle thirds and Hyflex CM to prepare the apical third
Study NCT03285022 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial caries removel techniques
Description: Removel of all superfacial dentin and leaving the inner affectted dentin
Study NCT03285022 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial caries removel techniques
Description: Removel of all superfacial dentin and leaving the inner affectted dentin
Study NCT03618355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eRapa (encapsulated rapamycin)
Description: The eRapa (encapsulated rapamycin) drug product consists of sub-micron rapamycin particles incorporated into poly(methyl methacrylate) polymer (Eudragit® L 100 / S 100).~This improved formulation and better bioavailability enables eRapa to consistently provide approximately 30% more drug than sirolimus (unpublished data). Improved and predictable delivery allows for consistent and sustained lower dosing, which will result in an improved toxicity profile since the latter is proven to be related to blood concentration levels. This is a phase Ib trial in low risk (Gleason score ≤7 (3+4)) prostate cancer patients under active surveillance to establish dosage safety and treatment levels.
Study NCT00941629 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy (CPT)
Description: Patients with PTSD receive a trauma-focused, cognitive-behavioral intervention in Face-to -Face treatment.
Study NCT00941629 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Description: Provision of Cognitive Processing Therapy over teleconference network (telemental health; telehealth)
Study NCT00304083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV
Study NCT02029300 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Fiberoptic Intubation through the nasal route
Study NCT00304083 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Patients undergo surgery
Study NCT02029300 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Fiberoptic intubation through the oral route
Study NCT03629275 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CTX0E03 Drug Product and delivery device
Description: Includes stereotactic surgery and a burr hole drilled through the skull to allow for a one time intracerebral injection of 20 million CTX0E03 Drug Product stem cells into an area of the brain adjacent to the area affected by the stroke.
Study NCT03629275 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Sham surgical comparator includes stereotactic surgery and a partial thickness burr hole drilled into the skull. No injection of any kind is made into the brain, and no other intervention is given.
Study NCT01489813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genistein
Description: 30 mg of genistein supplement by mouth three times daily (PO TID).
Study NCT01489813 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Sugar pills will be taken by mouth three times daily (PO TID).
Study NCT02754700 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular Training
Description: Standardized, comprehensive neuromuscular training
Study NCT02754700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hip Focused ROBUST Training
Description: Biofeedback training focused on the hip extensors
Study NCT02754700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Knee Focused ROBUST Training
Description: Biofeedback training focused on knee abduction
Study NCT01170533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omeprazole and pantoprazole
Description: The clopidogrel dose will be a 600mg loading dose followed by a 75mg daily maintenance dose, starting the next day for 7 days. Omeprazole will be used at a daily dose of 40mg and pantoprazole at 80mg.
Study NCT00304083 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients undergo radiotherapy
Study NCT02420210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine Hydrochloride
Description: Given IV
Study NCT02420210 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV
Study NCT02420210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT02420210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02420210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01388465 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile phone text messaging
Description: Daily assessment followed by feedback
Study NCT04167410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: glycaemic management protocol implemented to clinic
Description: Following the introduction of the glycaemic management protocol to the clinic, data on the patients in the intervention group was collected prospectively between June 2018 and December 2018. Data of the patients in the intervention group was collected after the patient applied to the hospital for surgery or just after the decision on surgery was taken. Patients in the intervention group whose HbA1C values exceeded 7% were referred to endocrinology specialists prior to surgery. Glycaemic management of these patients was evaluated at the department of endocrinology and medications or doses of insulin and oral antidiabetics were changed when necessary. Glycaemic management was conducted by nurses in line with the protocolConsequently, the glycaemic management of patients during the perioperative period was conducted by general surgery nurses according to the protocol.
Study NCT03356821 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells
Description: One dose of 50x10\^6 bone marrow-derived allogeneic MSCs via the nasal route as soon as possible after confirmation of the stroke (in the middle cerebral artery), but within the first week of onset of presenting clinical symptoms. Within 30 minutes after cleaning the nose with saline, using standard procedures operative at the Neonatal Intensive Care Unit, the MSC will be delivered.
Study NCT02410928 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: direct laringoscopy
Description: the vocal cords will be visualized after extubation with direct laringoscopy
Study NCT02410928 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fiberoptic nasal laringoscopy
Description: the vocal cords will be visualized after extubation with fiberoptic nasal laringoscopy
Study NCT02410928 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasonograph
Description: the vocal cords will be visualized after extubation with fiberoptic ultrasonography
Study NCT01194492 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Albumin transcapillary escape rate (125I-albumin)
Description: Repeated measure by injection of 0.1 megabecquerel and 0.3 megabecquerel of 125-iodine labeled albumin before surgery and 2 days after surgery, respectively.
Study NCT01256684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vaginal suppository
Study NCT01256684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA
Description: Vaginal suppository containing 0.25% (3.25 mg) DHEA; daily dosing with one suppository for 12 weeks.
Study NCT01256684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA
Description: Vaginal suppository containing 0.50% (6.5 mg) DHEA; daily dosing with one suppository for 12 weeks.
Study NCT00064753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Multivitamin
Description: Vitamin B6 (Pyridoxine HCl): 50 mg Folic acid: 5.0 mg Vitamin B12: 1.0 mg Vitamin B1 (Thiamine HNO3): 1.5 mg Vitamin B2 (Riboflavin): 1.5 mg Vitamin C (Ascorbic Acid): 60 mg d-Biotin: 300 mcg Niacinamide: 20 mg Pantothenic Acid Calcium Pantothenate): 10 mg
Study NCT00064753 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Multivitamin
Description: Vitamin B6 (Pyridoxine HCl): 1.4 mg Folic acid: 0.0 mg Vitamin B12: 2.0 mcg Vitamin B1 (Thiamine HNO3): 1.5 mg Vitamin B2 (Riboflavin): 1.5 mg Vitamin C (Ascorbic Acid): 60 mg d-Biotin: 300 mcg Niacinamide: 20 mg Pantothenic Acid Calcium Pantothenate): 10 mg
Study NCT03236207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test extensively hydrolyzed formula
Description: extensively hydrolyzed formula with HMOs
Study NCT03236207 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control extensively hydrolyzed formula
Description: extensively hydrolyzed formula without HMOs
Study NCT01174680 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cardiogoniometry
Description: In the course of the project a cardiogoniometry will be carried out during the ambulant or residential hospitalization before the coronary angiography.
Study NCT02951962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Twynsta 80/5mg
Description: Hypertension
Study NCT02951962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crestor 20mg
Description: Hyperlipidemia
Study NCT02636959 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: saline irrigation
Description: HVSI (NeilMed® Sinus Rinse™) versus LVSI (Salinex®) in the early post-operative management in patients with chronic rhinosinusitis. Both are a saline rinse spray.
Study NCT00976664 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shoe orthotic
Description: Shoe orthotics are devices worn in the shoe to modify the patient's stance and gait.
Study NCT00976664 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Shoe Orthotic Wait Group
Description: This group receives the custom-made shoe orthotics at week 6 of the 12 week treatment program rather than week 1.
Study NCT03834870 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES)
Description: Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES) screening tool.
Study NCT03117452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Training
Description: The computerized visual training (VT) program that is being evaluated was developed by Aaron Seitz, who is a co-investigator on this project; it includes 1) ULTIMEYES, which targets broad-based visual functions, including low-level processes (e.g., visual acuity, contrast sensitivity), and 2) visual perceptual organization exercises, which target mid-level visual processes. Both elements of the program also involve higher-level visual functions, such as visual search and visual attention.
Study NCT02731742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-101
Description: SD-101 administered as an intratumoral (IT) injection
Study NCT01191112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peptide based enteral formula
Description: Sole source nutrition as per HCP
Study NCT03855501 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mineral trioxide aggregate
Description: Apexification treatment was done with mineral trioxide aggregate
Study NCT03855501 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Calcium hydroxide
Description: Apexification treatment was done with calcium hydroxide
Study NCT01770327 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Effect of ingestion of different Sugary Beverages on Thirst Sensation
Description: The participants will drink Water (control group),Non-fat Milk, Orange Juice and Iced Tea. The beverages will be presented chilled but without ice in 330 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min.
Study NCT01770327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effect of ingestion of different Sugary Beverages on Thirst Sensation
Description: The participants will drink Water (control group),Non-fat Milk, Orange Juice and Iced Tea. The beverages will be presented chilled but without ice in 330 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min.
Study NCT05085509 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US guidance and MB staining
Description: Ultrasound guidance and methylene blue staining
Study NCT05085509 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US guidance and MB staining
Description: Ultrasound guidance and methylene blue staining
Study NCT03844009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer integrated debriefing
Description: At the end of each computer-based simulation, the participant had a computer integrated debriefing of his performance during the neonatal resuscitation simulation and a debriefing based on an auto-evaluation of his non-technical skills.
Study NCT03157531 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: B-Laser™ Atherectomy System
Description: The B-Laser™ is indicated for use for atherectomy of infrainguinal stenoses
Study NCT00331006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab by slow intravenous infusion; for participants greater than or equal to 10 kg, 375 mg per m\^2 BSA weekly for 4 weeks; for participants less than 10 kg, 12.5 mg/kg weekly for 4 weeks
Study NCT02736903 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PennFit mobile individual intervention
Description: PennFit (individual) is a mobile app intervention. Participants received a Fitbit physical activity tracking device and an introductory physical activity promotion session emphasizing the health benefits of physical activity and building skills for daily exercises. Participants used the PennFit app (individual) to record and monitor their own physical activity progress.
Study NCT02736903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PennFit mobile online network intervention
Description: PennFit (online network) is a mobile app intervention. Participants received a Fitbit physical activity tracking device and an introductory physical activity promotion session emphasizing the health benefits of physical activity and building skills for daily exercises. Participants used the PennFit app (online network) to record and monitor their own physical activity progress. They could see both their own information and the profiles and activity logs of the three other women assigned to their network. In addition, they could send messages to the network through an instant chatting tool.
Study NCT00579813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 30mg for 2 weeks, then Pioglitazone 45mg for 8 weeks.
Study NCT03098108 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concurrent chemo-proton therapy
Description: Proton therapy with simultaneous integrated boost technique Gross tumor volume 70.4 gray (Gy)/ 16 fractions and clinical target volume 44.8 Gy/16 fractions Capecitabine twice a day 825 mg/body square meter